Biopharmaceutical Tier-2 Diagnostic Tools for Chronic Neuropenia and Osteoporosis: A New Approach to Aerospace Medicine

Research Article

Volume 6, Issue 9 (September Issue)

Biopharmaceutical Tier-2 Diagnostic Tools for Chronic Neuropenia and Osteoporosis: A New Approach to Aerospace Medicine

V Lunde Dadon^1*, V Lyinda Dadiyane², Vivian Wolfsson³ and Simone Bridgsson⁴

¹Oak Ridge Aerospace Institute DOE, DPO Outlying Islands
²Fleet Ecology Institute on Metallurgic Studies, DPO Outlying Island
³Lofton Epigenetics Laboratories, DPO Outlying Islands, Jan Mayen Svalbaard
⁴Bio_RAD and Bio_MED Research Center Artic Circle, DPO, Bouvet Islands

^*Corresponding author: V Lunde Dadon, Oak Ridge Aerospace Institute DOE, DPO Outlying Islands. E-mail: mllcsage808@gmail.com

Received: August 14, 2024; Accepted: August 27, 2024; Published: September 15, 2024

Citation: Dadon VL, Dadiyane VL, Wolfsson V, et al. Biopharmaceutical Tier-2 Diagnostic Tools for Chronic Neuropenia and Osteoporosis: A New Approach to Aerospace Medicine. Clin Image Case Rep J. 2024; 6(9): 419.

Download PDF

Biopharmaceutical Tier-2 Diagnostic Tools for Chronic Neuropenia and Osteoporosis: A New Approach to Aerospace Medicine

Abstract

Biopharmaceutical Industry has introduced a new method to treat Chronic Neutropenia, and Osteoporosis by the treatment call AeroPharma. This is a New Approach to Biopharmaceutical in the field of Aerospace, AeroFlights Operations, and hyperbaric chambers. In this case study will take deep dive into the process of simulation of the peptides from B. Subtillis, as it provides two tier of secreted hormones used in the treatment of Aerospace Medical Cases, such as catalyst hormone in Teraparatide and Filgrastism. Our staff worked very diligently in generating 2-Tier Reports Classifiable Drugs, the sequencing of the phases of initiation of treatment, Regional Drug Compliance, and treatment, and outcomes.